PeptiDream
Business Services · Japan · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
3-25-23 Tonomachi, Tonomachi, Kanagawa, ...Phone Number
+81 442701300Website
www.peptidream.comRevenue
$176.2 MillionStock Symbol
4587Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About PeptiDream
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing their proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.Explore more
PeptiDream Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PeptiDream your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on PeptiDream recently announced quarterly report
Funding: Get notified immidiatlly once PeptiDream has new funding data
Congratulate Masked Content for being promoted to Masked Content at PeptiDream
Check out if PeptiDream is spiking on competitors!
PeptiDream, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if PeptiDream had a recent Job posting/layoffs
Check if PeptiDream has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PeptiDream launches new products
Recommended Actions
Reach out to Masked Content who joined PeptiDream as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
PeptiDream is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PeptiDream is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PeptiDream.
PeptiDream Tech Stack
A closer look at the technologies used by PeptiDream
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
PeptiDream News & Media
PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript
PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call February 16, 2026 2:00 AM ESTCompany ParticipantsYuko Okimoto - IR & Public Relations DirectorPatrick...Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies’ registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC).PeptiDream Inc. (PPTDF) Discusses Progress in Radiopharmaceuticals and Peptide Therapeutics Pipeline Transcript
PeptiDream Inc. (OTCPK:PPTDF) Discusses Progress in Radiopharmaceuticals and Peptide Therapeutics Pipeline December 5, 2025 1:30 AM ESTCompany...Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PeptiDream
Sign Up For FreeTo access detailed company insights
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing their proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for... Read More
